As chemotherapy is recommended as the 1st-line treatment in the patients with stage IV NSCLC without EGFR mutation, ALK fusion gene arrangement or unknown for these gene mutation statuses in NCCN guideline, we recommend that IBC be considered a 1st-line treatment for NSCLC patients with stage IIIB or IV, especially for the patients without above mutation or gene arrangement. This evidence concerns the gene EGFR and non-small cell lung carcinoma.